Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Using FXIa-triggered thrombin generation to assess the risk of breakthrough bleeding in patients receiving emicizumab for acquired Hemophilia A

Fabius Pelzer, Ella Ertekin, Olga Oleshko, Annika Klingberg, Paul Knoebl, Christian Pfrepper, Richard Greil, Johannes Oldenburg, Ulrich Sachs, Wolfgang Miesbach, Karolin Trautmann-Grill, Katharina Holstein, Hermann Eichler, Patrick Moehnle, Christina Hart, Robert Klamroth, Andreas Tiede, Sonja Werwitzke

Blood (2025) 146 (Supplement 1): 310.

https://doi.org/10.1182/blood-2025-310

Published: 2025

Journal Articles

Novel von willebrand factor targeting thrombolytic TGD001 is safe and well tolerated in a phase 1 first-in-human trial

Marie Scully, Spero Cataland, Paul Coppo, Paul Knoebl, Paul Brinkkoetter, Javier de la Rubia, Marielle Klein Hesselink, Josefin-Beate Holz, Flora Peyvandi

Blood (2025) 146 (Supplement 1): 849.

https://doi.org/10.1182/blood-2025-849

Published: 2025

Journal Articles

Recombinant ADAMTS13 prophylaxis in patients with congenital thrombotic thrombocytopenic purpura: Final analysis from A phase 3 randomized, controlled study

Blood (2025) 146 (Supplement 1): 848.

https://doi.org/10.1182/blood-2025-848

Published: 2025

Journal Articles

Saliva of persons with hemophilia A triggers coagulation via extrinsic tenase complexes

Johannes Thaler, Carla Tripisciano, Daniel Kraemmer, Chi Hau, Nazanin Samadi, Wolfram Ruf, Ingrid Pabinger, Paul Knoebl, Rienk Nieuwland, Cihan Ay

Blood (2024) 144 (25): 2666–2677.

https://doi.org/10.1182/blood.2024025093

Published: 2024

Includes: Supplemental data

Journal Articles

Management of Immune Thrombotic Thrombocytopenic Purpura without Therapeutic Plasma Exchange: Analysis of Efficacy and Safety Data

Lucas Kühne, Paul Knoebl, Kathrin Eller, Ingrid Pabinger, Paul T. Brinkkoetter, Linus A. Voelker

Blood (2023) 142 (Supplement 1): 4001.

https://doi.org/10.1182/blood-2023-181159

Published: 2023

Journal Articles

The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies

Johanna A. Kremer Hovinga Strebel, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knoebl, Flora Peyvandi, Spero Cataland, PAUL Coppo, Umer Khan, Laurel A. Menapace, Ana Paula Marques, Sriya Gunawardena, Marie Scully

Blood (2022) 140 (Supplement 1): 5651–5653.

https://doi.org/10.1182/blood-2022-156306

Published: 2022

Journal Articles

Treatment Burden and Patient Preference in Patients with Hemophilia A or B with Inhibitors on Concizumab Prophylaxis: Results from the Phase 3 explorer7 Study

Kingsley Hampton, Paul Knoebl, Jan Odgaard-Jensen, Oleksandra Stasyshyn, Jay Jay Thaung Zaw, Jesper Skov Neergaard, Bulent Zulfikar

Blood (2022) 140 (Supplement 1): 5591–5592.

https://doi.org/10.1182/blood-2022-163468

Published: 2022

Journal Articles

Safer steps on a narrow path

Paul Knoebl

Blood (2022) 140 (18): 1923–1924.

https://doi.org/10.1182/blood.2022017947

Published: 2022

Journal Articles

Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study

Marie Scully, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knoebl, Flora Peyvandi, Spero Cataland, Paul Coppo, Johanna A. Kremer Hovinga Strebel, Jessica Minkue Mi Edou, Rui de Passos Sousa, Filip Callewaert, Sriya Gunawardena, Julie Lin

Blood (2021) 138 (Supplement 1): 2080.

https://doi.org/10.1182/blood-2021-148839

Published: 2021

Journal Articles

NT-Probnp As Personalized Medicine Tool and New Biomarker Predicting Response to Chemotherapy and Survival in AML

Irene Graf, Georg Greiner, Rodrig Marculescu, Karoline V. Gleixner, Susanne Herndlhofer, Gabriele Stefanzl, Paul Knoebl, Ulrich Jaeger, Alexander Hauswirth, Ilse Schwarzinger, Renate Thalhammer, Michael Kundi, Gregor Hoermann, Gerlinde Mitterbauer-Hohendanner, Peter Valent, Wolfgang R. Sperr

Blood (2021) 138 (Supplement 1): 3435.

https://doi.org/10.1182/blood-2021-149526

Published: 2021

Journal Articles

Emicizumab for the treatment of acquired hemophilia A

Paul Knoebl, Johannes Thaler, Petra Jilma, Peter Quehenberger, Karoline Gleixner, Wolfgang R. Sperr

Blood (2021) 137 (3): 410–419.

https://doi.org/10.1182/blood.2020006315

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Katerina Pavenski, MD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Flora Peyvandi, MD PhD, Spero Cataland, MD, Ara Metjian, MD, Javier De La Rubia, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2365.

https://doi.org/10.1182/blood-2019-123126

Published: 2019

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

Paul Coppo, MD PhD, Spero Cataland, MD, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2366.

https://doi.org/10.1182/blood-2019-123720

Published: 2019

Journal Articles

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Spero Cataland, MD, Marie Scully, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Filip Callewaert

Blood (2019) 134 (Supplement_1): 4908.

https://doi.org/10.1182/blood-2019-123124

Published: 2019

Journal Articles

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Javier De La Rubia, Flora Peyvandi, MD PhD, Marie Scully, Spero Cataland, MD, Paul Coppo, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Paul Knoebl, MD, Ara Metjian, MD, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 1093.

https://doi.org/10.1182/blood-2019-124004

Published: 2019

Journal Articles

Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases

Paul Knoebl, MD, Wolfgang R. Sperr, Peter Schellongowski, MD, Thomas Staudinger, MD, Petra Jilma-Stohlawetz, MD, Peter Quehenberger, MD, Silvia Koder, Ing, Cihan Ay, MD, Karoline V. Gleixner, MD

Blood (2018) 132 (Supplement 1): 2476.

https://doi.org/10.1182/blood-2018-99-116973

Published: 2018

Journal Articles

A Registry Study on Treatment of Patients with Acquired Protein C Deficiency with a Protein C Concentrate (Human)

Paul Knoebl, MD, Michael Sasse, MD, Maria Pia De Carolis, MD, Jacqueline A Dyck-Jones, PhD, Sandra Ehrle, MD, Maureen Finnerty, David Gelmont, MD, Leman Yel, MD, Mahmoud Loghman-Adham, MD, Doris Fischer, MD

Blood (2016) 128 (22): 3816.

https://doi.org/10.1182/blood.V128.22.3816.3816

Published: 2016

Journal Articles

Pharmacodynamic Profile of a Recombinant ADAMTS13 (BAX930) in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome (USS))

Marie Scully, Paul Knoebl, MD, Karim Kentouche, Lawrence Rice, MD, Jerzy Windyga, MD, Reinhard Schneppenheim, Johanna A Kremer Hovinga, MD PhD, Michiko Kajiwara, Caterina Maggiore, Jennifer Doralt, Leah Martell, Bruce M. Ewenstein

Blood (2016) 128 (22): 135.

https://doi.org/10.1182/blood.V128.22.135.135

Published: 2016

Journal Articles

Intensive Post-Remission Consolidation with G-CSF-Support: Tolerability, Safety, Reduced Hospitalization, and Efficacy of a New Treatment Protocol for AML Patients ≥60 Years

Wolfgang R. Sperr, MD, Susanne Herndlhofer, Karoline V Gleixner, MD, Michael Girschikofsky, MD, Ansgar Weltermann, MD, Sigrid Machherndl-Spandl, MD, Thamer Sliwa, MD, Rainer Poehnl, MD, Buxhofer-Ausch Veronika, MD, Karin Strecker, MD, Paul Knoebl, MD, Ulrich Jaeger, Klaus Geissler, MD, Michael Kundi, MD, Peter Valent, MD

Blood (2016) 128 (22): 2797.

https://doi.org/10.1182/blood.V128.22.2797.2797

Published: 2016

Journal Articles

Registry Of Patients Treated With Protein C Concentrate (Human) In The United States and Europe: Interim Results

Marilyn J. Manco-Johnson, MD, Paul Knoebl, MD, Amy D. Shapiro, MD, Maureen Finnerty, RN, MS, Leman Yel, MD, David Gelmont, MD

Blood (2013) 122 (21): 1146.

https://doi.org/10.1182/blood.V122.21.1146.1146

Published: 2013

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Using FXIa-triggered thrombin generation to assess the risk of breakthrough bleeding in patients receiving emicizumab for acquired Hemophilia A

Novel von willebrand factor targeting thrombolytic TGD001 is safe and well tolerated in a phase 1 first-in-human trial

Recombinant ADAMTS13 prophylaxis in patients with congenital thrombotic thrombocytopenic purpura: Final analysis from A phase 3 randomized, controlled study

Saliva of persons with hemophilia A triggers coagulation via extrinsic tenase complexes

Management of Immune Thrombotic Thrombocytopenic Purpura without Therapeutic Plasma Exchange: Analysis of Efficacy and Safety Data

The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies

Treatment Burden and Patient Preference in Patients with Hemophilia A or B with Inhibitors on Concizumab Prophylaxis: Results from the Phase 3 explorer7 Study

Safer steps on a narrow path

Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study

NT-Probnp As Personalized Medicine Tool and New Biomarker Predicting Response to Chemotherapy and Survival in AML

Emicizumab for the treatment of acquired hemophilia A

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases

A Registry Study on Treatment of Patients with Acquired Protein C Deficiency with a Protein C Concentrate (Human)

Pharmacodynamic Profile of a Recombinant ADAMTS13 (BAX930) in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome (USS))

Intensive Post-Remission Consolidation with G-CSF-Support: Tolerability, Safety, Reduced Hospitalization, and Efficacy of a New Treatment Protocol for AML Patients ≥60 Years

Registry Of Patients Treated With Protein C Concentrate (Human) In The United States and Europe: Interim Results

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only